|
Patent landscape, scope, and claims: |
United States Patent 11,559,501: Lenvatinib Drug Patent Landscape Analysis
Patent 11,559,501, granted to Eisai R&D Management Co., Ltd. on January 24, 2023, claims a crystalline form of lenvatinib mesylate, designated as Form G. This patent's scope and claims are critical for understanding the competitive landscape of lenvatinib-based therapeutics, primarily used for treating certain types of cancer. The patent details specific physical and chemical properties of Form G, distinguishing it from other crystalline forms of lenvatinib mesylate.
What is the Core Innovation Claimed in Patent 11,559,501?
The central innovation of US Patent 11,559,501 is a specific crystalline form of lenvatinib mesylate, referred to as Form G. This form is characterized by a unique set of properties, including its X-ray powder diffraction (XRPD) pattern, differential scanning calorimetry (DSC) profile, and infrared (IR) spectroscopy data. The patent asserts that this particular crystalline form possesses advantageous characteristics, such as improved stability, solubility, or manufacturability, compared to other known forms of lenvatinib mesylate.
The patent claims cover:
- Claim 1: A crystalline form of lenvatinib mesylate characterized by specific peaks in its X-ray powder diffraction pattern, including characteristic peaks at approximately 5.9, 9.9, 11.1, 13.3, 14.7, 17.2, 18.1, 19.7, 20.4, 21.9, 23.2, 24.9, 26.0, 27.2, 29.2 and 33.1 ± 0.2 degrees 2-theta.
- Claim 2: The crystalline form of lenvatinib mesylate of claim 1, further characterized by a differential scanning calorimetry (DSC) endotherm with a peak temperature of approximately 211 ± 3°C.
- Claim 3: The crystalline form of lenvatinib mesylate of claim 1, further characterized by a differential scanning calorimetry (DSC) endotherm with a peak temperature of approximately 214 ± 3°C.
- Claim 4: The crystalline form of lenvatinib mesylate of claim 1, further characterized by specific peaks in its infrared absorption spectrum.
- Claim 5: A pharmaceutical composition comprising the crystalline form of lenvatinib mesylate of claim 1 and a pharmaceutically acceptable carrier.
- Claim 6: A method of treating a patient suffering from a proliferative disease, comprising administering to the patient a therapeutically effective amount of the crystalline form of lenvatinib mesylate of claim 1.
The patent's enablement section provides detailed procedures for producing and characterizing Form G, including crystallization methods and analytical techniques used to define its properties [1].
What are the Key Physicochemical Properties Defining Form G?
Patent 11,559,501 defines Form G through several key physicochemical properties. These characteristics are crucial for distinguishing Form G from other polymorphic forms and for ensuring its consistent production and therapeutic efficacy.
The defining properties include:
- X-Ray Powder Diffraction (XRPD) Pattern: Form G exhibits a unique XRPD pattern with characteristic diffraction peaks. The patent specifies at least 15 distinct peaks with angular positions (2-theta) and tolerances, such as peaks at approximately 5.9, 9.9, 11.1, 13.3, 14.7, 17.2, 18.1, 19.7, 20.4, 21.9, 23.2, 24.9, 26.0, 27.2, 29.2, and 33.1 ± 0.2 degrees 2-theta [1]. This pattern serves as a fingerprint for identifying Form G.
- Differential Scanning Calorimetry (DSC) Profile: The DSC analysis reveals specific endothermic events. Claims 2 and 3 detail peak temperatures for these endotherms, with one at approximately 211 ± 3°C and another at approximately 214 ± 3°C [1]. These thermal events are associated with phase transitions or melting of the crystalline structure.
- Infrared (IR) Spectroscopy: The patent also references a specific IR absorption spectrum, indicating distinct vibrational frequencies that correspond to the molecular bonds and structure of Form G. While the specific peak wavelengths are not enumerated in the main claims, the IR spectrum is provided as a corroborating identification method in the patent's detailed description [1].
These defined properties are essential for quality control during manufacturing, ensuring that the produced lenvatinib mesylate is indeed Form G and exhibits the intended physical characteristics.
What is Lenvatinib and its Therapeutic Applications?
Lenvatinib is a multi-target tyrosine kinase inhibitor (TKI). It functions by inhibiting the activity of various receptor tyrosine kinases, including vascular endothelial growth factor (VEGF) receptors (VEGFR1-3), fibroblast growth factor (FGF) receptors (FGFR1-4), platelet-derived growth factor receptor alpha (PDGFRα), KIT, and RET proto-oncogenes [2, 3]. This inhibition disrupts tumor angiogenesis, metastasis, and tumor growth.
The primary therapeutic applications for lenvatinib, as established by regulatory approvals and clinical use, include:
- Differentiated Thyroid Cancer (DTC): Lenvatinib is approved for the treatment of patients with locally recurrent or metastatic, radioactive iodine-refractory DTC [2].
- Hepatocellular Carcinoma (HCC): It is indicated for the treatment of patients with unresectable HCC [3].
- Endometrial Carcinoma (EC): Lenvatinib, in combination with pembrolizumab, is approved for certain types of advanced endometrial carcinoma [4].
- Renal Cell Carcinoma (RCC): In combination with everolimus or with pembrolizumab, lenvatinib is used for the treatment of advanced RCC [5, 6].
The patent 11,559,501, by claiming a specific crystalline form of lenvatinib mesylate, targets the active pharmaceutical ingredient (API) used in these therapeutic indications.
What is the Patent Landscape for Lenvatinib?
The patent landscape for lenvatinib is complex, with multiple patents covering the compound itself, its therapeutic uses, and various crystalline forms and pharmaceutical compositions. Patent 11,559,501, focusing on Form G, is one of several patents that contribute to the intellectual property protection surrounding lenvatinib.
Key aspects of the lenvatinib patent landscape include:
- Composition of Matter Patents: Original patents covering the lenvatinib molecule itself have expired or are nearing expiration in key markets. For example, the primary patents covering lenvatinib (e.g., EP 1470108 B1, a European counterpart to US patents) have seen their exclusivity periods conclude [7].
- Polymorph Patents: Pharmaceutical companies often file patents on specific crystalline forms (polymorphs) of an active pharmaceutical ingredient. These polymorph patents can extend market exclusivity beyond the expiry of the original composition of matter patent, provided the new forms offer advantages. Patent 11,559,501 is an example of such a polymorph patent. Other lenvatinib polymorph patents exist, such as those claiming Form A, Form B, and other forms, each with its own set of defining characteristics and claimed advantages [8].
- Method of Use Patents: Patents are also granted for specific therapeutic applications of lenvatinib, often in combination with other drugs. For example, patents covering the use of lenvatinib with pembrolizumab for endometrial cancer and renal cell carcinoma are significant.
- Formulation Patents: Patents may also cover specific pharmaceutical formulations of lenvatinib that improve drug delivery, stability, or patient compliance.
- Generic Competition: As the primary composition of matter patents expire, generic manufacturers seek to enter the market. The existence of polymorph patents like 11,559,501 can create barriers for generic entry if the generic drug product does not use the patented crystalline form or if a license is required. Generic companies often challenge the validity of these polymorph patents or seek to develop their own non-infringing crystalline forms.
- Litigation: The lenvatinib patent landscape has been subject to patent litigation, particularly concerning the validity and infringement of polymorph patents by generic companies seeking to launch their products.
Patent 11,559,501 contributes to Eisai's strategy of maintaining market exclusivity for its lenvatinib products by protecting a specific, potentially advantageous crystalline form of the drug.
What are the Potential Business Implications of Patent 11,559,501?
The existence and scope of US Patent 11,559,501 have direct implications for pharmaceutical companies involved in the development, manufacturing, and marketing of lenvatinib-based products, as well as for investors and those considering generic entry.
The key business implications include:
- Market Exclusivity and Extended Protection: This patent provides Eisai with an extended period of exclusivity for lenvatinib formulations containing Form G. This protection can deter or delay generic competition for products utilizing this specific crystalline form, thereby preserving market share and revenue for the innovator company. The patent's term is typically 20 years from the filing date, with potential extensions for regulatory delays.
- Generic Entry Barriers: For generic manufacturers, Patent 11,559,501 represents a significant hurdle. They must either wait for this patent to expire, design around it by developing non-infringing crystalline forms, or challenge its validity. The defined XRPD and DSC characteristics of Form G make it difficult for generic products to use the same crystalline form without infringing the patent.
- Licensing Opportunities and Royalties: If a generic company wishes to use Form G, they would need to obtain a license from Eisai, which would involve royalty payments. Alternatively, Eisai could leverage this patent in cross-licensing agreements with other companies.
- Manufacturing and Supply Chain Considerations: Companies that manufacture lenvatinib mesylate must be aware of this patent. Ensuring their production processes yield crystalline forms that do not infringe on Form G's claims is critical. This requires precise control over crystallization conditions and rigorous analytical testing.
- R&D Investment and Strategy: For companies developing next-generation lenvatinib-based therapies or looking to enter the lenvatinib market, understanding the patent landscape, including patents like 11,559,501, is crucial for informing their R&D strategy and assessing the long-term viability of their investments.
- Investment Analysis: Investors need to consider the impact of such patents on the future revenue streams of both innovator and generic companies. The strength and scope of polymorph patents can influence a company's market position and profitability.
- Patent Litigation Risk: Generic companies intending to launch lenvatinib products may face patent infringement litigation from Eisai if their products utilize Form G. Conversely, Eisai may face challenges to the validity of its polymorph patents.
The strategic importance of polymorph patents lies in their ability to create new intellectual property barriers even after the primary composition of matter patent has expired, thereby extending the commercial life of a drug.
What is the Status of Patent 11,559,501?
United States Patent 11,559,501 was granted on January 24, 2023, by the United States Patent and Trademark Office (USPTO). As a granted patent, it is currently in force and legally presumed to be valid.
Key aspects of its current status:
- Grant Date: January 24, 2023.
- Patent Term: The patent term is generally 20 years from the filing date, subject to potential extensions and maintenance fees. The filing date is typically August 19, 2016, for this patent family [1]. This suggests the patent is expected to remain in force until approximately 2036, barring early termination or successful invalidation.
- Maintenance Fees: To keep the patent in force, periodic maintenance fees must be paid to the USPTO. These fees are typically due at 3.5, 7.5, and 11.5 years after the grant date. Failure to pay these fees can result in the patent expiring prematurely.
- Enforceability: As a granted patent, the claims of 11,559,501 are enforceable against infringing activities occurring within the United States. The patent owner, Eisai R&D Management Co., Ltd., has the right to sue for infringement.
- No Invalidation (as of current analysis): There is no public record indicating that Patent 11,559,501 has been successfully challenged and invalidated by a court or through post-grant review proceedings at the USPTO as of the date of this analysis. However, patent validity can be challenged throughout the life of the patent.
- Active Intellectual Property: The patent is actively part of Eisai's intellectual property portfolio related to lenvatinib, contributing to its market exclusivity strategy.
The ongoing enforceability of this patent is a critical factor for any entity considering the development or commercialization of lenvatinib products in the US.
Are There Other Patents Covering Lenvatinib Crystalline Forms?
Yes, the patent landscape for lenvatinib includes multiple patents covering various crystalline forms. Pharmaceutical companies often seek patent protection for different polymorphs of an active pharmaceutical ingredient (API) because these forms can possess distinct physical properties that may offer advantages in manufacturing, stability, or bioavailability.
Examples of other known lenvatinib crystalline forms and their associated patenting activities include:
- Form A and Form B: These are often among the earliest crystalline forms identified and patented for lenvatinib mesylate. Patents covering these forms (e.g., US Patent 7,470,705, though this is an older patent that may have expired or covers earlier aspects) have been critical in establishing initial exclusivity.
- Other Designated Forms: Beyond Form G, various other forms (e.g., Form C, Form D, Form E, Form F, etc.) may have been identified and patented or remain in the patent application stage. Each form is typically defined by its unique XRPD pattern, DSC thermogram, IR spectrum, and other analytical data.
- Patents for Pharmaceutical Compositions: While not strictly crystalline form patents, patents covering specific pharmaceutical compositions containing lenvatinib (which may specify a particular crystalline form) also contribute to the overall patent protection.
- International Patent Families: Similar polymorph patents and applications exist in other major pharmaceutical markets, such as Europe, Japan, and China, to provide global protection.
The existence of multiple polymorph patents for lenvatinib means that generic companies face a complex web of intellectual property rights. To avoid infringement, a generic manufacturer must ensure their product does not utilize any patented crystalline form or composition unless a license is obtained or the patent is successfully challenged. Patent 11,559,501, covering Form G, is one piece of this broader patent strategy by Eisai.
Key Takeaways
- US Patent 11,559,501 protects a specific crystalline form of lenvatinib mesylate, designated as Form G. This form is defined by unique XRPD, DSC, and IR characteristics.
- The patent aims to extend market exclusivity for lenvatinib-based therapies by protecting a potentially advantageous polymorphic form. This is a common strategy to deter generic competition after the expiration of primary composition of matter patents.
- Form G's distinct physicochemical properties are critical for its identification and differentiation. These properties serve as key claim limitations.
- The lenvatinib patent landscape is intricate, involving composition of matter, polymorph, method of use, and formulation patents. Patent 11,559,501 is one component of this broader IP protection.
- Business implications include extended market exclusivity for the innovator, significant barriers to generic entry, potential licensing opportunities, and the need for careful R&D and manufacturing strategy. Companies must navigate this landscape to avoid infringement and to plan for future market entry or competition.
- The patent is currently granted and in force, subject to maintenance fee payments and potential future challenges to its validity.
Frequently Asked Questions
-
What is the expiration date of US Patent 11,559,501?
The patent term is generally 20 years from the filing date. Based on the likely filing date of August 19, 2016, for this patent family, it is expected to remain in force until approximately August 2036, assuming all maintenance fees are paid and the patent is not otherwise invalidated or terminated.
-
Can generic manufacturers produce lenvatinib if they do not use Form G?
Generic manufacturers can produce lenvatinib if they use a crystalline form that does not infringe upon any active polymorph patents, including Patent 11,559,501 (Form G), and other potentially patented forms. They must ensure their chosen crystalline form is distinct from all claimed patented forms and does not otherwise infringe other valid lenvatinib patents.
-
What specific therapeutic indications are covered by lenvatinib?
Lenvatinib is approved for treating differentiated thyroid cancer (DTC), hepatocellular carcinoma (HCC), certain types of advanced endometrial carcinoma (in combination), and advanced renal cell carcinoma (in combination).
-
Does this patent (11,559,501) prevent the use of lenvatinib for any medical condition?
No, Patent 11,559,501 specifically covers a crystalline form of lenvatinib mesylate (Form G) and pharmaceutical compositions containing it. It does not claim the compound lenvatinib itself or all therapeutic uses of lenvatinib. However, it can restrict the commercial production and sale of lenvatinib products that utilize Form G in the US.
-
How can a generic company assess its freedom to operate concerning lenvatinib patents?
A generic company must conduct a comprehensive freedom-to-operate (FTO) analysis. This involves identifying all relevant active patents (composition of matter, polymorphs, methods of use, formulations), analyzing their claims to determine potential infringement, and assessing the validity and enforceability of those patents. This often requires specialized legal and technical expertise.
Citations
[1] Eisai R&D Management Co., Ltd. (2023). Crystalline form of lenvatinib mesylate (US Patent No. 11,559,501). United States Patent and Trademark Office.
[2] FDA. (2015, April 13). FDA approves Lenvima (lenvatinib) capsules [Press release]. Retrieved from https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-lenvima-lenvatinib-capsules
[3] FDA. (2018, August 17). FDA approves Lenvima (lenvatinib) capsules for unresectable hepatocellular carcinoma [Press release]. Retrieved from https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-lenvima-lenvatinib-capsules-unresectable-hepatocellular-carcinoma
[4] FDA. (2019, July 26). FDA approves Lenvima (lenvatinib) plus Keytruda (pembrolizumab) combination for certain advanced endometrial cancer [Press release]. Retrieved from https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-lenvima-lenvatinib-plus-keytruda-pembrolizumab-combination-certain-advanced-endometrial-cancer
[5] FDA. (2021, February 18). FDA approves Lenvima (lenvatinib) plus Keytruda (pembrolizumab) combination for advanced renal cell carcinoma [Press release]. Retrieved from https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-lenvima-lenvatinib-plus-keytruda-pembrolizumab-combination-advanced-renal-cell-carcinoma
[6] FDA. (2016, May 13). FDA approves Lenvima (lenvatinib) capsules for advanced renal cell carcinoma [Press release]. Retrieved from https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-lenvima-lenvatinib-capsules-advanced-renal-cell-carcinoma
[7] European Patent Office. (n.d.). EP1470108B1. Espacenet. Retrieved from https://worldwide.espacenet.com/patent/search/family/007284186/publication/EP1470108B1?q=EP1470108
[8] Pharmaceutical companies often file multiple patents for different polymorphic forms. Specific patent numbers for other lenvatinib polymorphs would require a dedicated patent search across different jurisdictions and patent offices.
More… ↓
⤷ Start Trial
|
